Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia

Analytical and Quantitative Cytology and Histology

Volumn 30, Issue 4, 2008, Pages 199-202

  Voss, Martin ^a   Trojan, Lutz ^a   Steidler, Annette ^a   Weiss, Christel ^a   Grobholz, Rainer ^a   Alken, Peter ^a   Michel, Maurice Stephan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer, prostate; Hyperplasia, lymphatic; Vascular endothelial growth factor C

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; VASCULOTROPIN C;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 49649125849     PISSN: 08846812     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wetterwald A, Hoffstetter W, Cecchini MG, Lanske B, Wagner C, Fleisch H, Atkinson M: Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996;18:125-132
2. Wigle JT, Harvey N, Detmar M, Lagutina I, Grosveld G, Gunn MD, Jackson DG, Oliver G: An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002; 21:1505-1513
3. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566-3570
4. Kahn HJ, Marks A: A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257
5. Jackson DG, Prevo R, Clasper S, Banerji S: LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001;22:317-321
6. Soh S, Ishii T, Sato E, Akishima Y, Ito K, Baba S: Topographic distribution of lymphatic vessels in normal human prostate. Prostate 2005;63:330-335
7. Stacker SA, Williams RA, Achen MG: Lymphangiogenic growth factors as markers of tumor metastasis. APMIS 2004; 112:539-549
8. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, Ayala G: Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004;58:193-199
9. Jennbacken K, Vallbo C, Wang W, Damber JE: Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005;65:110-116
10. Tsurusaki T, Kanda S, Sakai H, Kanetake H Saito Y, Alitalo K, Koji T: Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer 1999;80:309-313
11. Trojan L, Rensch F, Voss M, Grobholz R, Weiss C, Jackson DG, Alken P, Michel MS: The role of the lymphatic system and its specific growth factor, vascular endothelial growth factor C, for lymphogenic metastasis in prostate cancer. BJU Int 2006;98:903-906
12. Mitsuhashi A, Suzuka K, Yamazawa K, Matsui H, Seki K, Sekiya S: Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer 2005;103:724-730
13. Tamura M, Ohta Y: Serum vascular endothelial growth factor-C level in patients with primary nonsmall cell lung carcinoma: A possible diagnostic tool for lymph node metastasis. Cancer 2003;98:1217-1222
14. Kitadai Y, Kodama M, Cho S, Kuroda T, Ochiumi T, Kimura S, Tanaka S, Matsumura S, Yasui W, Chayama K: Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int J Cancer 2005;115:388-392
15. Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K: Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res Treat 2005; 91:125-132
16. Trojan L, Michel MS, Rensch F, Jackson DG, Alken P, Grobholz R: Lymph and blood vessel architecture in benign and malignant prostatic tissue: Lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol 2004;172:103-107
17. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK: Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 2004;64:4400-4404
18. Wong SY, Haack H, Crowley D, Barry M, Bronson RT, Hynes RO: Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis. Cancer Res 2005;65:9789-9798
19. Pytowski B, Goldman J, Persaud K, Wu Y, Witte L, Hicklin DJ, Skobe M, Boardman KC, Swartz MA: Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005;97:14-21
20. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K: Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002;94:819-825